James Corbett - 04 Jun 2025 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Role: CEO, Director
Signature: /s/ Nicole Kelsey, by power of attorney
Issuer symbol: RCEL
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Jun 2025, 16:30:10 UTC
Previous filing: 06 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
CORBETT JAMES	CEO, Director	28159 AVENUE STANFORD, SUITE 220 - AVITA MEDICAL, VALENCIA	/s/ Nicole Kelsey, by power of attorney	05 Jun 2025	0001238620

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCEL	Stock Options (Right to Buy)	Award	$0	+520,000		$0.000000	520,000	21 Jan 2025	Common Stock	520,000	$8.73	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
F2	These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025.

Content

On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025.